MedTrace Logo

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

NCT02159066 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 158

Last updated 2024-03-05

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to assess the anti-tumor activity of LGX818/MEK162 in combination with targeted agents after progression on LGX818/MEK162 combination therapy, as well as the safety and tolerability of the novel triple combinations.

Conditions

Interventions

DRUG

LGX818

Combination of LGX818 and MEK162 (Part I)

DRUG

MEK162

Combination of LGX818 and MEK162 (Part I)

DRUG

LEE011

Combination of LGX818 + MEK162 + LEE011 (Part II)

DRUG

BGJ398

Combination of LGX818 + MEK162 + BGJ398 (Part II)

DRUG

BKM120

Combination of LGX818 + MEK162 + BKM120 (Part II)

DRUG

INC280

Combination of LGX818 + MEK162 + INC280 (Part II)

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-23
Primary Completion
2023-01-10
Completion
2023-01-10

Countries

  • United States
  • Australia
  • Canada
  • Germany
  • Italy
  • Netherlands
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02159066 on ClinicalTrials.gov